异基因造血干细胞移植急性移植物抗宿主病诊断与治疗中国专家共识(2024年版)  

Chinese expert consensus on the diagnosis and treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation (2024)

作　　者：中华医学会血液学分会干细胞应用学组 黄晓军[2] 吴德沛[3] 张晓辉[2] 徐郑丽[2] 刘代红[4] 赵翔宇[2] 张曦 Hematopoietic Stem Cell Application Group,Chinese Society of Hematology,Chinese Medical Association;Huang Xiaojun;Wu Depei;Zhang Xiaohui(不详;Peking University People's Hospital,Beijing 100044,China;the First Affiliated Hospital of Soochow Universityy,Suzhou 215006,China)

机构地区：[1]不详 [2]北京大学人民医院,北京100044 [3]苏州大学附属第一医院,苏州215006 [4]解放军总医院第一医学中心 [5]陆军军医大学第二附属医院

出　　处：《中华血液学杂志》2024年第6期525-533,共9页Chinese Journal of Hematology

摘　　要：尽管异基因造血干细胞移植(allo-HSCT)的疗效不断改善,急性移植物抗宿主病(GVHD)仍然是主要的合并症和死亡原因。近年来,随着急性GVHD防治新型药物的出现及系列临床研究的更新,常规急性GVHD预防及治疗方案有着不同程度的变化。基于近年来在该领域的主要研究成果和临床经验的积累,本共识在《中国异基因造血干细胞移植治疗血液系统疾病专家共识——急性移植物抗宿主病(2020年)》基础上做进一步更新。Despite the continuous improvement in the efficacy of allogeneic hematopoietic stem cell transplantation(allo-HSCT),acute graft-versus-host disease(GVHD)remains a major complication and cause of death.In recent years,with the emergence of new drugs for the prevention and treatment of acute GVHD and the update of a series of clinical studies,there have been varying degrees of changes in the routine prevention and treatment regimens for acute GVHD.Based on the main research achievements and the accumulation of clinical experience in this field in recent years,this consensus further updates the"The Consensus on Allogeneic Hematopoietic Stem Cell Transplantation for Hematological Diseases in China-Acute Graft-Versus-Host Disease(2020).

关 键 词：异基因造血干细胞移植 急性移植物抗宿主病 

分 类 号：R457.7[医药卫生—治疗学]